ProMIS Neurosciences Inc. (PMN)
NASDAQ: PMN
· Real-Time Price · USD
0.45
-0.09 (-16.14%)
At close: Sep 03, 2025, 3:59 PM
-16.14% (1D)
| Bid | 0.44 |
| Market Cap | 14.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.43M |
| EPS (ttm) | -0.07 |
| PE Ratio (ttm) | -6.41 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.45 |
| Volume | 49,296,852 |
| Avg. Volume (20D) | 7,139,446 |
| Open | 0.50 |
| Previous Close | 0.54 |
| Day's Range | 0.42 - 0.52 |
| 52-Week Range | 0.38 - 1.59 |
| Beta | -0.03 |
Analyst Forecast
According to 0 analyst ratings, the average rating for PMN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 days ago
PMN stock has given up its prior gain. PMN up: Pro...
Unlock content with
Pro Subscription
2 days ago
PMN up: ProMIS Neurosciences shares are trading higher after the Data and Safety Monitoring Board recommended the company proceed to the third dose escalation cohort in its PRECISE-AD Phase 1b Alzheimer's trial.
2 years ago · proactiveinvestors.com
ProMIS Neurosciences submits IND application for Alzheimer's treatmentProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's di...